Anal Cancer Survivorship Follow-Up Questions

Most anal cancer is treated without removing the anus. That single fact shapes everything that follows.

NCI calls definitive chemoradiation the standard of care for stage I, II and III disease. Radiation is given with fluorouracil and mitomycin. Two alternatives are listed. One is capecitabine with mitomycin. The other is fluorouracil with cisplatin. Small tumors of the perianal skin can be removed locally, if the sphincter is not involved.

Radical resection is not the first move. NCI states plainly that it is reserved for incomplete responses or recurrent disease.

So the sphincter stays. Bowel control stays. And the price of that choice is a follow-up schedule that has to be taken seriously.

Many survivorship pages talk about follow-up in the abstract. This one does not need to.

NCI states it outright. After sphincter-preserving therapy, surveillance means a rectal examination every 3 months for the first 2 years. Endoscopy with biopsy is added when indicated.

Three months. Not six. Not annually. And the examination is a physical one, done by a clinician, not a scan.

The schedule is hunting for residual or recurrent tumor in the anal canal. It wants to find it while salvage surgery still works. NCI also notes a second option. Salvage chemoradiation with fluorouracil and cisplatin, plus a radiation boost, may avoid a permanent colostomy in some people with residual tumor.

The trials behind this treatment were not measuring tumor shrinkage alone. They were measuring whether people kept their bowel.

In the RTOG/ECOG trial of 310 patients, adding mitomycin to fluorouracil and radiation improved colostomy-free survival at 4 years, 71% against 59%. Disease-free survival went from 51% to 73%.

RTOG 98-11 compared mitomycin with cisplatin. Mitomycin gave better local control and better colostomy-free survival, 90% against 81%. Long-term follow-up showed 5-year disease-free survival of 67.8% against 57.8%.

That is why mitomycin is still in the regimen despite its toxicity. The endpoint it wins on is the one that decides whether someone lives with a stoma.

NCI addresses this directly rather than in passing.

In general, people with HIV are treated the same way as everyone else, and outcomes are similar in the era of effective antiretroviral therapy. That is the headline.

The qualification is specific. A pretreatment CD4 count below 200 cells per microliter may mean more acute and late toxicity. Someone with a history of AIDS-related complications may struggle with a standard regimen. NCI says this can mean a dose adjustment, or leaving mitomycin out.

NCI also records why the risk is higher in the first place. People with HIV have a higher rate of HPV coinfection, and therefore a higher risk of anal cancer.

Ninety-five percent of anal cancers are HPV related. NCI puts the highest risk on types 16 and 18, and notes that HPV involvement can be correlated pathologically with p16-positive staining.

That is worth carrying into survivorship, because HPV is not confined to one site. NCI's vaccine fact sheet lists anal cancers among the cancers HPV causes.

On vaccination after a diagnosis, NCI's position is careful. Routine vaccination runs through age 26. For adults aged 27 through 45 it is not routinely recommended. Clinicians can instead discuss whether it is right for one person. The benefit is smaller at that age, because more people have already been exposed. The vaccine is safe in people already infected. It simply works best before exposure.

NCI is unusually direct here. Anal cancer, it says, is usually curable.

Two things drive prognosis: tumor size and node status. Primary tumors under 2 cm do better. Nodal drainage follows the inguinal vein, so the groin is examined carefully at diagnosis and any palpable node is biopsied.

Most people present with T1 or T2 disease, meaning 5 cm or less. Fewer than 20% have node-positive disease. For those early-stage patients, 5-year survival exceeds 85%. Even with positive nodes, 5-year survival exceeds 50%, as long as there is no invasion of nearby organs and no distant spread.

Those figures are group averages, not forecasts. They do explain why the treatment aims for cure and the follow-up is built around catching failure early.

Fluorouracil and capecitabine are broken down by an enzyme encoded by the DPYD gene.

NCI estimates that 1% to 2% of people carry germline DPYD variants that reduce that enzyme's function. Patients with the DPYD*2A variant who receive these drugs can experience severe, sometimes fatal toxicity. Depending on genotype, avoidance or a 50% dose reduction may be recommended.

NCI adds the practical trade-offs. The test costs under $200, insurance coverage varies because there is no national guideline, and testing can delay treatment by 2 weeks. It calls the issue controversial and unresolved.

One gap is worth naming. NCI's anal cancer treatment summary does not mention retifanlimab anywhere.

NCI's own drug page does. It lists retifanlimab-dlwr, brand name Zynyz. It is approved for adults with squamous cell anal carcinoma that has spread or come back. It is given with carboplatin and paclitaxel as first treatment, when surgery cannot remove the cancer. It is given alone after platinum chemotherapy stops working, or when platinum cannot be used.

Two NCI pages, two different pictures. For anyone whose disease has become advanced, that is a gap worth raising rather than assuming the treatment summary is current.

For the disease itself, see anal cancer. For life after treatment more broadly, see survivorship and fear of recurrence.

• NCI PDQ — Anal Cancer Treatment (Health Professional Version)
• NCI — Retifanlimab-dlwr
• NCI — Human Papillomavirus (HPV) Vaccine